Home |
Free Dividend Report |
Stock Splits Calendar |
OCX Stock Split History |
Preferred Stock Newsletter |
OCX Options Chain |
Stock Message Boards |
Oncocyte (OCX) has 1 split in our OCX split history database. The split for OCX took place on July 25, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of OCX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Oncocyte conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the OCX split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Oncocyte shares, starting with a $10,000 purchase of OCX, presented on a split-history-adjusted basis factoring in the complete OCX split history.
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 01/05/2016 | |
End date: | 04/26/2024 | |
Start price/share: | $202.20 | |
End price/share: | $2.48 | |
Dividends collected/share: | $0.00 | |
Total return: | -98.77% | |
Average Annual Total Return: | -41.12% | |
Starting investment: | $10,000.00 | |
Ending investment: | $122.61 | |
Years: | 8.31 |
About Oncocyte |
Oncocyte is a precision diagnostics company focused on developing and commercializing proprietary tests in three areas: DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, VitaGraft is a blood-based solid organ transplantation monitoring test and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. According to our OCX split history records, Oncocyte has had 1 split. |
OCX Split History Table | |
Date | Ratio |
07/25/2023 | 1 for 20 |
Healthcare Stock Splits |
OCX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
OGEN Split History
Free OCX Email Alerts:
|
OCX Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved
Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.Want to receive our latest research absolutely free?
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.